Inflammatory bowel disease(IBD)is a complex condition,for which standardized diagnostics and treatment are paramount to enhance medical efficacy.Chinese consensus/guidelines for IBD management were formulated in 1978,...Inflammatory bowel disease(IBD)is a complex condition,for which standardized diagnostics and treatment are paramount to enhance medical efficacy.Chinese consensus/guidelines for IBD management were formulated in 1978,1993,2001,2007,2012,and 2018,and markedly standardized and improved the clinical management of IBD in China.Recently,given the rising incidence of IBD in China,[1]related clinical and basic research has received much attention.The depth of evidence is increasing,which has laid a solid foundation for updating the consensus guideline.展开更多
The role of Chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease(IBD)is self-evident.As clinical and basic research in China becomes standar...The role of Chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease(IBD)is self-evident.As clinical and basic research in China becomes standardized under a better understanding of IBD,more data on Chinese patients have become available to develop a consensus and guideline.This guideline,collaboratively developed by the IBD Group,Chinese Society of Gastroenterology,incorporates the latest international consensus statements,[1-7]domestic research findings,and practical considerations,as an update based on the 2018 Chinese consensus on IBD management.[8]The IBD guideline consists of two parts:ulcerative colitis(UC)and Crohn’s disease,and this manuscript presented the UC part.The evidence used in this guideline was collected and analyzed by the standard of guideline,and the contents were organized as problem statements,for clarity.The formulation of this guideline aimed to reflect the latest progress in IBD,providing comprehensive and valuable guidance for the clinical management of IBD.展开更多
基金funded by grants from the National Key R&D Program(No.2023YFC2507300)Guangdong R&D Program in Key Fields(No.2023B1111040003).
文摘Inflammatory bowel disease(IBD)is a complex condition,for which standardized diagnostics and treatment are paramount to enhance medical efficacy.Chinese consensus/guidelines for IBD management were formulated in 1978,1993,2001,2007,2012,and 2018,and markedly standardized and improved the clinical management of IBD in China.Recently,given the rising incidence of IBD in China,[1]related clinical and basic research has received much attention.The depth of evidence is increasing,which has laid a solid foundation for updating the consensus guideline.
基金funded by the National Key R&D Program(No.2023YFC2507300)Guangdong R&D Program in Key Fields(No.2023B1111040003).
文摘The role of Chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease(IBD)is self-evident.As clinical and basic research in China becomes standardized under a better understanding of IBD,more data on Chinese patients have become available to develop a consensus and guideline.This guideline,collaboratively developed by the IBD Group,Chinese Society of Gastroenterology,incorporates the latest international consensus statements,[1-7]domestic research findings,and practical considerations,as an update based on the 2018 Chinese consensus on IBD management.[8]The IBD guideline consists of two parts:ulcerative colitis(UC)and Crohn’s disease,and this manuscript presented the UC part.The evidence used in this guideline was collected and analyzed by the standard of guideline,and the contents were organized as problem statements,for clarity.The formulation of this guideline aimed to reflect the latest progress in IBD,providing comprehensive and valuable guidance for the clinical management of IBD.
